Results 11 to 20 of about 24,874 (200)

Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease

open access: yesJournal of Pharmacological Sciences, 2015
The therapeutic response rates of patients to donepezil vary from 20% to 60%, one of the reasons is their genetic differences in donepezil-metabolizing enzymes, which directly influence liver metabolism. However, the mechanism of donepezil metabolism and
Jin Lu   +9 more
doaj   +2 more sources

Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect

open access: yesJournal of Pharmacological Sciences, 2019
Oxaliplatin induces severe peripheral neuropathy. The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models.
Takehiro Kawashiri   +4 more
doaj   +2 more sources

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients

open access: yesClinical Interventions in Aging, 2018
Nan Zhang,1,2 Marc L Gordon3,4 1Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Tianjin, People’s Republic of China; 2Department of Neurology and Neurosurgery, Tianjin Medical University ...
Zhang N, Gordon ML
doaj   +1 more source

Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers

open access: yesDrug Design, Development and Therapy, 2015
Yo Han Kim,1 Hee Youn Choi,1 Hyeong-Seok Lim,1 Shi Hyang Lee,1 Hae Sun Jeon,1 Donghyun Hong,2 Seong Su Kim,2 Young Kweon Choi,2 Kyun-Seop Bae1 1Department of Clinical Pharmacology and Therapeutics, College of Medicine, University of Ulsan, Asan Medical ...
Kim YH   +8 more
doaj   +1 more source

Design, Synthesis and Molecular Docking Studies of Some Novel Hydrazone Derivatives Based on Trimetazidine as Selective and Potent AChE Inhibitors. [PDF]

open access: yesDrug Dev Res
ABSTRACT Alzheimer's disease (AD) is a progressive neurodegenerative disease, and cholinergic dysfunction is considered one of the fundamental pathological factors of this disease. Guided by the clinically used acetylcholinesterase (AChE) inhibitor donepezil, we explored trimetazidine dihydrochloride as an accessible starting scaffold to generate ...
Doğan MO   +6 more
europepmc   +2 more sources

Design, Synthesis, and Biological Evaluation of Molecular Hybrids Incorporating Coumarin-Pyrazole-Linked Indolinone Derivatives With Antioxidant and Anti-Alzheimer Properties. [PDF]

open access: yesChem Biodivers
ABSTRACT The increase in global life expectancy has resulted in a significant rise in the occurrence of Alzheimer's disease (AD), making it a critical public health burden. Therefore, there is an urgent need to create effective methods to prevent or slow down the progression of the disease.
Sabt A   +6 more
europepmc   +2 more sources

Donepezil Potentiates Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells

open access: yesJournal of Pharmacological Sciences, 2007
Donepezil is a potent and selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer’s disease. To elucidate whether donepezil causes neuronal differentiation, we examined its effect on nerve growth factor (NGF)-induced neurite ...
Toru Oda   +5 more
doaj   +1 more source

The effects of donepezil in Alzheimer's disease - Results from a multinational trial [PDF]

open access: yes, 1999
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD).
Hecker, J.   +7 more
core   +1 more source

The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer’s disease patients: study protocol for a randomized controlled trial

open access: yesTrials, 2017
Background Alzheimer’s disease is a progressive neurodegenerative disease. Although some of the current treatments offer some symptomatic relief, this disease cannot be cured at present.
Weina Peng   +5 more
doaj   +1 more source

Clinicial and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review [PDF]

open access: yes, 2001
Background Alzheimer’s disease is the most common cause of dementia and is characterised by an insidious onset and slow deterioration. The estimated prevalence of Alzheimer’s disease for a standard health authority (500,000 people) is about 3330. Current
A. Clegg   +18 more
core   +1 more source

Home - About - Disclaimer - Privacy